Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 11/20 | 0.73 |
| ▸ | AURKA | O14965 | 10/20 | 0.73 |
| ▸ | KDR | P35968 | 10/20 | 0.67 |
| ▸ | FLT3 | P36888 | 3/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.67 |
| ▸ | FYN | P06241 | 2/20 | 0.67 |
| ▸ | LYN | P07948 | 2/20 | 0.67 |
| ▸ | GSK3B | P49841 | 2/20 | 0.67 |
| ▸ | BLK | P51451 | 2/20 | 0.67 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.67 |
| ▸ | STK3 | Q13188 | 2/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.67 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.67 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.67 |
| ▸ | IKBKB | O14920 | 1/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.67 |
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | PIM1 | P11309 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708728 | 0.88 | AURKB (0.80) | AURKBAURKAKDRFLT3LCK | |
| SCHEMBL709155 | 0.86 | AURKB (0.77) | AURKBAURKAKDRFLT3LCK | |
| SCHEMBL707252 | 0.85 | AURKA (0.83) | AURKBAURKAKDRFLT3LCK | |
| SCHEMBL711213 | 0.85 | AURKB (0.71) | AURKBAURKAKDRFLT3LCK | |
| SCHEMBL709079 | 0.84 | AURKB (1.00) | AURKBAURKAKDRFLT3LCK | |
| SCHEMBL710637 | 0.84 | AURKB (1.00) | AURKBAURKAKDRFLT3LCK | |
| SCHEMBL15221984 | 0.84 | KDR (0.57) | AURKBAURKAKDRFLT3LCK | |
| SCHEMBL707878 | 0.82 | AURKA (0.72) | AURKBAURKAKDRFLT3LCK | |
| SCHEMBL15221878 | 0.82 | KDR (0.56) | AURKBAURKAKDRFLT3LCK | |
| SCHEMBL15221911 | 0.82 | KDR (0.57) | AURKBAURKAKDRFLT3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124759-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-28 | — | — | US | claimed |
| EP-2297151-A1 | INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009136966-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | WO | claimed |
| US-20090131425-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | claimed |
| US-8124759-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2297151-A1 | INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009136966-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090131425-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131425-A1 | INHIBITORS OF PROTEIN KINASES | AURKC, AURKB, PLK1 | AURKB 2/4885AURKA 4/4885KDR 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.